Home › Compare › LTHUQ vs ABBV
LTHUQ yields 20000000.00% · ABBV yields 3.09%● Live data
📍 LTHUQ pulled ahead of the other in Year 1
Combined, LTHUQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LTHUQ + ABBV for your $10,000?
Lithium Technology Corporation engages in the design, manufacture, marketing, and delivery of rechargeable energy storage solutions. The company designs and builds large format cylindrical lithium-ion (Li-ion) rechargeable cells, as well as Li-ion rechargeable batteries with battery management systems for use in transportation, military/national security, and stationary power markets. Its product portfolio includes large format high power cells ranging from 7.5 to 45 Ah with high discharge capabilities designed for HEV and military applications; high energy cells ranging from 10 to 485 Ah for various applications, such as back-up power and remote standby installations; large batteries up to 600V and capacity of more than 1.2 MWh; and standard cells that are assembled into custom large batteries complete with electronics to manage the batteries. The company markets its products to industrial, retail, and government customers, as well as to scientific research facilities and national defense agencies primarily in the United States, United Kingdom, and Germany. Lithium Technology Corporation is headquartered in Fairfax, Virginia. On December 5, 2014, Lithium Technology Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Virginia.On June 12, 2015, the voluntary petition of Lithium Technology Corp. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on December 5, 2014.
Full LTHUQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.